Clinical analysis of HIV/AIDS patients with drug eruption in Yunnan, China.
Clinical analysis of HIV/AIDS patients with drug eruption in Yunnan, China.
复制标题
云南省HIV/AIDS患者药疹临床分析
DOI：
10.1038/srep35938
复制
发表时间：
2016-10-31
影响因子：
4.6
通讯作者：
Kuang YQ
中科院分区：
文献类型：
--
作者：
Li YY;Jin YM;He LP;Bai JS;Liu J;Yu M;Chen JH;Wen J;Kuang YQ
药疹是HIV/AIDS患者最常见的临床表现。与药疹相关的全身性临床和危险因素仍不清楚。回顾性分析HIV/AIDS药疹患者的人口学资料、流行病学资料、临床特征、实验室检查资料及随访资料。采用病例对照分析方法对影响预后的危险因素进行分析。在1817例HIV/AIDS患者中，共有134例（7.4%）出现药疹。致敏药物主要为高效抗逆转录病毒药物（47.7%），其次为抗生素（47.0%）。奈韦拉平（39.6%）是HAART方案中最常见的致敏药物。接受HAART治疗或有过敏史的患者易发生药疹。药疹患者的丙氨酸氨基转移酶、白蛋白、球蛋白、肌酐、尿素氮、淋巴细胞、红细胞、嗜酸性粒细胞与对照组比较有显著性差异。过敏史、机会性感染、病毒载量、CD 4细胞计数、高球蛋白、低白蛋白是HIV/AIDS药疹患者死亡的危险因素。建议对病毒载量较高、球蛋白水平较高和白色血细胞（WBC）较低的患者应给予特别关注，以预防并发症和死亡。
Drug eruption is the most common clinical presentation in patients with HIV/AIDS. The systemic clinical and risk factors associated with drug eruption remain unknown. A retrospective analysis in HIV/AIDS patients with drug eruption was carried out with demographic data, epidemiological data, clinical characteristics, laboratory data and follow-up data. The risk factors correlated with prognosis were assessed by case control analysis. A total of 134 out of 1817 HIV/AIDS patients (7.4%) presented drug eruptions. The major class of sensitizing drug was HAART drugs (47.7%), followed by antibiotics (47.0%). Nevirapine (39.6%) was the most common sensitizing drug in the HAART regimens. The patients received HAART or had allergic history were prone to develop drug eruption. The alanine aminotransferase, albumin, globulin, creatinine, blood urea nitrogen (BUN), lymphocytes, red blood cells (RBC) and eosinophils of the drug eruption patients were significantly different the control patients. The allergic history, opportunistic infection, viral load, CD4 cell count, high globulin and low albumin were the risk factors correlated with death in HIV/AIDS patients with drug eruption. It is proposed that patients with higher viral loads, higher globulin levels and lower white blood cells (WBC) should be given special attention for the prevention of complications and death.
登录
查看更多内容
DOI：
10.5588/ijtld.10.0698
发表时间：
2011-12-01
影响因子：
4
作者：
Lehloenya, R. J.;Todd, G.;Dheda, K.
通讯作者：
Dheda, K.
DOI：
10.1111/j.1468-3083.2011.04429.x
发表时间：
2013-03-01
影响因子：
9.2
作者：
Han, J.;Lun, W. H.;Lian, S.
通讯作者：
Lian, S.
影响因子：
158.5
作者：
COOPMAN, SA;JOHNSON, RA;STERN, RS
通讯作者：
STERN, RS
影响因子：
7.7
作者：
Hernandez-Salazar, Amparo;Ponce-de-Leon Rosales, Samuel;Orozco-Topete, Rocio
通讯作者：
Orozco-Topete, Rocio
影响因子：
3.4
作者：
Lee CI;Kwon SY;Kim JH;Choe WH;Lee CH;Yoon EL;Yeon JE;Byun KS;Kim YS;Kim JH
通讯作者：
Kim JH